Guidance Guidance
This guidance replaces previous guidance on laparoscopic radical hysterectomy for early stage cervical cancer (interventional procedure guidance 24). 1.1 Current evidence on the efficacy and safety of laparoscopic radical hysterectomy for early stage cervical cancer is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit. 1.2 Patient selection should be carried out by a multidisciplinary gynaecological oncology team. The procedure should be carried out in units specialising in the treatment of gynaecological malignancies. The International Federation of Gynecology and Obstetrics (FIGO) system is used to stage cervical cancer from I to IV. Early stage cervical cancer includes stages I (cancer confined to the cervix) to IIA (tumour invades the cervix with endocervical glandular involvement only).
2.1.3
Early stage cervical cancer is usually treated by radical hysterectomy.
Radiotherapy may be used, with or without surgery, and is usually combined with chemotherapy. More advanced cervical cancer is generally treated with radiotherapy and chemotherapy. The non-randomised comparative study of 127 patients reported that significantly fewer lymph nodes were removed in patients treated by laparoscopic radical hysterectomy than abdominal radical hysterectomy (mean 23.5 and 25.2 respectively) (p < 0.01).
2.3.6
The Specialist Advisers listed key efficacy outcomes as completing the This guidance was developed using the NICE interventional procedure guidance process.
It updates and replaces NICE interventional procedure guidance 24.
We have produced a summary of this guidance for patients and carers. Information about the Laparoscopic radical hysterectomy for early stage cervical cancer (IPG338)
